Genetically engineered immunotoxin shows early promise in patients with B-cell malignancies

DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data.
Source: ScienceDaily Headlines - Category: Science Source Type: news